Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Gross Profit: 2020-2025

Historic Gross Profit for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $53.8 million.

  • Tango Therapeutics' Gross Profit rose 363.61% to $53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.5 million, marking a year-over-year increase of 53.28%. This contributed to the annual value of $42.1 million for FY2024, which is 15.17% up from last year.
  • Tango Therapeutics' Gross Profit amounted to $53.8 million in Q3 2025, which was up 1,591.64% from $3.2 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Gross Profit high stood at $53.8 million for Q3 2025, and its period low was $3.2 million during Q2 2025.
  • Its 3-year average for Gross Profit is $12.8 million, with a median of $6.5 million in 2024.
  • Over the last 5 years, Tango Therapeutics' Gross Profit had its largest YoY gain of 363.61% in 2025, and its largest YoY loss of 83.99% in 2025.
  • Tango Therapeutics' Gross Profit (Quarterly) stood at $5.7 million in 2021, then increased by 12.16% to $6.4 million in 2022, then decreased by 15.29% to $5.4 million in 2023, then declined by 24.19% to $4.1 million in 2024, then surged by 363.61% to $53.8 million in 2025.
  • Its Gross Profit was $53.8 million in Q3 2025, compared to $3.2 million in Q2 2025 and $5.4 million in Q1 2025.